InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,751.64
(
-0.07%
)
Post# of 6280
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

sts66

Send PM Follow Ignore
Followers 74
Posts 15839
Boards Moderated 0
Alias Born 04/26/2010

sts66

Re: maytepper post# 6269

Friday, 12/05/2014 4:08:42 PM

Friday, December 05, 2014 4:08:42 PM

Post# of 6280
What is this guy smoking? Raises PT to $20 despite saying no other bidders are in sight?

Cowen analyst Ritu Baral maintained an Outperform rating on Avanir Pharmaceuticals (NASDAQ:AVNR) with a $20 price target, following the news that the company has entered into a definitive agreement with Otsuka Pharmaceutical pursuant to which Otsuka will acquire Avanir for $17.00 per share in cash.

Baral observed, “We see this as an underwhelming offer but see no evidence of other bidders before the tender offer begins in 10 business days and the close of the transaction in 1Q15.

The Thought Police: To censor and protect. Craig Bruce

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up